Literature DB >> 2996688

Persistence of antibrain antibodies in cerebrospinal fluid during plasmapheresis for multiple sclerosis.

B Ryberg, R Pirskanen.   

Abstract

A man with chronic progressive multiple sclerosis received a 10 day course of treatment with adrenocorticotrophic hormone without beneficial effect. He then received six sessions of plasmapheresis, again without improvement. Treatment with adrenocorticotrophic hormone had no effect on serum antibrain antibody titres, but plasmapheresis virtually eliminated the antibodies from serum and caused a fall in serum IgG concentrations; neither treatment had any effect on the IgG concentration and antibody titre in the cerebrospinal fluid. Treatment with plasmapheresis may fail in patients with multiple sclerosis because it does not remove antibrain antibodies from the intrathecal space.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996688      PMCID: PMC1416748          DOI: 10.1136/bmj.291.6499.850

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  3 in total

Review 1.  Therapeutic plasma exchange.

Authors:  K H Shumak; G A Rock
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

2.  Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis.

Authors:  D Stefoski; C L Schauf; B C McLeod; C P Haywood; F A Davis
Journal:  Neurology       Date:  1982-08       Impact factor: 9.910

3.  Antibrain antibodies in multiple sclerosis. Relation to clinical variables.

Authors:  B Ryberg
Journal:  J Neurol Sci       Date:  1982-05       Impact factor: 3.181

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.